Shots:
- Blackstone has closed Blackstone Life Sciences VI (BXLS VI) at its hard cap of $6.3B of total capital commitments, making it ~40% larger than its predecessor vehicle
- Blackstone launched BXLS platform in 2018, with ~$15B in assets under management as of Q4’25 & invests across the lifecycle of drugs and medtech, with an ~86% P-III approval success rate
- BXLS has committed ~$2B over the past 12mos. via partnerships with companies including Merck, Teva, Alnylam, & Novartis, reinforcing its position as an active participant in drug & medtech royalty transactions
Ref: Blackstone | Image: Blackstone | Press Release
Related News: Teva Lands $400M Blackstone Life Sciences Deal to Support Duvakitug Development
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
